<bill session="116" type="h" number="2905" updated="2019-10-22T07:16:04Z">
  <state datetime="2019-05-22">REFERRED</state>
  <status>
    <introduced datetime="2019-05-22"/>
  </status>
  <introduced datetime="2019-05-22"/>
  <titles>
    <title type="official" as="introduced">To provide for a demonstration project to further examine the benefits of providing coverage and payment for items and services necessary to administer intravenous immune globulin (IVIG) in the home, and for other purposes.</title>
    <title type="short" as="introduced">Medicare IVIG Access Enhancement Act</title>
    <title type="short" as="introduced">Medicare IVIG Access Enhancement Act</title>
    <title type="display">Medicare IVIG Access Enhancement Act</title>
  </titles>
  <sponsor bioguide_id="B000574"/>
  <cosponsors>
    <cosponsor bioguide_id="B001284" joined="2019-09-26"/>
    <cosponsor bioguide_id="B001251" joined="2019-05-22"/>
    <cosponsor bioguide_id="C001049" joined="2019-10-04"/>
    <cosponsor bioguide_id="D000598" joined="2019-08-06"/>
    <cosponsor bioguide_id="E000296" joined="2019-09-06"/>
    <cosponsor bioguide_id="F000466" joined="2019-10-21"/>
    <cosponsor bioguide_id="G000559" joined="2019-07-11"/>
    <cosponsor bioguide_id="H001065" joined="2019-05-22"/>
    <cosponsor bioguide_id="K000376" joined="2019-08-09"/>
    <cosponsor bioguide_id="K000385" joined="2019-06-03"/>
    <cosponsor bioguide_id="K000188" joined="2019-09-17"/>
    <cosponsor bioguide_id="L000591" joined="2019-09-06"/>
    <cosponsor bioguide_id="M001158" joined="2019-07-18"/>
    <cosponsor bioguide_id="M001163" joined="2019-09-06"/>
    <cosponsor bioguide_id="P000523" joined="2019-09-11"/>
    <cosponsor bioguide_id="S001185" joined="2019-07-15"/>
    <cosponsor bioguide_id="S001172" joined="2019-09-09"/>
  </cosponsors>
  <actions>
    <action datetime="2019-05-22">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-05-22">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR E657"/>
    </action>
    <action datetime="2019-05-22" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-05-22">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSWM" name="House Ways and Means" activity="Referral"/>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Drug therapy"/>
    <term name="Government studies and investigations"/>
    <term name="Home and outpatient care"/>
    <term name="Medicare"/>
    <term name="Neurological disorders"/>
  </subjects>
  <amendments/>
  <summary date="2019-05-22T04:00:00Z" status="Introduced in House">Medicare IVIG Access Enhancement Act

This bill requires the Centers for Medicare &amp; Medicaid Services to establish a three-year demonstration project to evaluate the benefits of providing Medicare coverage and payment for items and services needed for the in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy. Beneficiary participation shall be voluntary.</summary>
  <committee-reports/>
</bill>
